JP2011513316A - 眼疾患の治療のための黒大豆の使用 - Google Patents
眼疾患の治療のための黒大豆の使用 Download PDFInfo
- Publication number
- JP2011513316A JP2011513316A JP2010548810A JP2010548810A JP2011513316A JP 2011513316 A JP2011513316 A JP 2011513316A JP 2010548810 A JP2010548810 A JP 2010548810A JP 2010548810 A JP2010548810 A JP 2010548810A JP 2011513316 A JP2011513316 A JP 2011513316A
- Authority
- JP
- Japan
- Prior art keywords
- black soybean
- black
- product
- seed coat
- rpe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 89
- 244000068988 Glycine max Species 0.000 title claims abstract description 69
- 208000030533 eye disease Diseases 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 54
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 36
- 208000035475 disorder Diseases 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 239000012675 alcoholic extract Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000002904 solvent Substances 0.000 claims description 16
- 230000000242 pagocytic effect Effects 0.000 claims description 13
- 206010057249 Phagocytosis Diseases 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 230000008782 phagocytosis Effects 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 230000002207 retinal effect Effects 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000000790 retinal pigment Substances 0.000 claims description 4
- 206010038848 Retinal detachment Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000004264 retinal detachment Effects 0.000 claims description 3
- 230000004382 visual function Effects 0.000 claims description 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 27
- 239000000047 product Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 14
- 210000004358 rod cell outer segment Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000020712 soy bean extract Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108091008695 photoreceptors Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000004155 blood-retinal barrier Anatomy 0.000 description 3
- 230000004378 blood-retinal barrier Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960003981 proparacaine Drugs 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/036,565 US8883230B2 (en) | 2008-02-25 | 2008-02-25 | Use of black soybean for treating ophthalmic diseases |
| PCT/US2009/034712 WO2009108577A2 (en) | 2008-02-25 | 2009-02-20 | Use of black soybean for treating ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513316A true JP2011513316A (ja) | 2011-04-28 |
| JP2011513316A5 JP2011513316A5 (https=) | 2012-03-08 |
Family
ID=40998549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548810A Pending JP2011513316A (ja) | 2008-02-25 | 2009-02-20 | 眼疾患の治療のための黒大豆の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8883230B2 (https=) |
| EP (1) | EP2262515B1 (https=) |
| JP (1) | JP2011513316A (https=) |
| KR (1) | KR20110004370A (https=) |
| CN (1) | CN102036675B (https=) |
| AU (1) | AU2009219468B2 (https=) |
| CA (1) | CA2729129A1 (https=) |
| TW (1) | TWI488633B (https=) |
| WO (1) | WO2009108577A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9096795B2 (en) | 2009-05-22 | 2015-08-04 | Merck Patent Gmbh | Liquid crystal display |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160090662A (ko) * | 2015-01-22 | 2016-08-01 | 한국과학기술연구원 | 쥐눈이콩 추출물을 포함하는 망막질환의 예방 또는 치료용 조성물 |
| KR101838142B1 (ko) * | 2017-04-12 | 2018-03-14 | 한국과학기술연구원 | 쥐눈이콩 추출물을 포함하는 각막 질환의 예방 또는 치료용 조성물 |
| US12409202B2 (en) * | 2021-07-30 | 2025-09-09 | Fujicco Co., Ltd. | Autonomic nerve regulator and cognitive function improver |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077176A1 (en) * | 2004-02-11 | 2005-08-25 | The Trustees Of Columbia University In The City Of New York | Anthocyanin compounds and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028099A (en) * | 1998-03-13 | 2000-02-22 | John Hopkins University, School Of Medicine | Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization |
| US6001368A (en) * | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| JP4247833B2 (ja) | 2004-03-16 | 2009-04-02 | 株式会社ケーツーコミュニケーションズ | 視機能改善剤 |
| CN100390188C (zh) * | 2005-08-09 | 2008-05-28 | 广东省农业科学院农业生物技术研究所 | 一种黑大豆种皮花色苷的制备方法 |
| JP4873904B2 (ja) | 2005-08-22 | 2012-02-08 | 国立大学法人弘前大学 | 眼血管血流障害改善剤 |
| WO2008083513A1 (en) * | 2006-12-13 | 2008-07-17 | Beijing Gingko-Group Biological Technology Co., Ltd. | Black soybean hull extract and process for preparation and use thereof |
| US7820207B2 (en) * | 2007-03-15 | 2010-10-26 | Omnica Gmbh | Stabilized anthocyanin compositions |
| CN101062116A (zh) * | 2007-05-23 | 2007-10-31 | 王军 | 明目口服液 |
-
2008
- 2008-02-25 US US12/036,565 patent/US8883230B2/en not_active Expired - Fee Related
-
2009
- 2009-01-14 TW TW098101193A patent/TWI488633B/zh not_active IP Right Cessation
- 2009-02-20 CN CN2009801126894A patent/CN102036675B/zh not_active Expired - Fee Related
- 2009-02-20 AU AU2009219468A patent/AU2009219468B2/en not_active Ceased
- 2009-02-20 WO PCT/US2009/034712 patent/WO2009108577A2/en not_active Ceased
- 2009-02-20 CA CA2729129A patent/CA2729129A1/en not_active Abandoned
- 2009-02-20 EP EP09714471.1A patent/EP2262515B1/en not_active Not-in-force
- 2009-02-20 KR KR1020107021294A patent/KR20110004370A/ko not_active Withdrawn
- 2009-02-20 JP JP2010548810A patent/JP2011513316A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077176A1 (en) * | 2004-02-11 | 2005-08-25 | The Trustees Of Columbia University In The City Of New York | Anthocyanin compounds and methods of use thereof |
Non-Patent Citations (4)
| Title |
|---|
| JPN6013027370; Ｃｈｏｕｎｇ，Ｍｙｏｕｎｇ-Ｇｕｎ ｅｔ ａｌ: 'Ｉｓｏｌａｔｉｏｎ ａｎｄ Ｄｅｔｅｒｍｉｎａｔｉｏｎ ｏｆ Ａｎｔｈｏｃｙａｎｉｎｓ ｉｎ Ｓｅｅｄ Ｃｏａｔｓ ｏｆ Ｂｌａｃｋ Ｓｏｙｂｅａｎ （Ｇｌｙｃｉｎｅ ｍａｘ （Ｌ．） Ｍｅｒｒ．）' Ｊｏｕｒｎａｌ ｏｆ Ａｇｒｉｃｕｌｔｕｒａｌ ａｎｄ Ｆｏｏｄ Ｃｈｅｍｉｓｔｒｙ ４９（１２）, 2004, ｐｐ．５８４８-５８５１ * |
| JPN6013027372; Ｊａｎｇ， Ｙｏｕｎｇ Ｐ．ｅｔ ａｌ: 'Ａｎｔｈｏｃｙａｎｉｎｓ ｐｒｏｔｅｃｔ ａｇａｉｎｓｔ Ａ２Ｅ ｐｈｏｔｏｏｘｉｄａｔｉｏｎ ａｎｄ ｍｅｍｂｒａｎｅ ｐｅｒｍｅａｂｉｌｉｚａｔｉｏｎ ｉｎ ｒｅｔｉｎａｌ ｐｉｇｍｅｎｔ ｅｐｉ' Ｐｈｏｔｏｃｈｅｍｉｓｔｒｙ ａｎｄ Ｐｈｏｔｏｂｉｏｌｏｇｙ ８１（Ｍａｙ／Ｊｕｎｅ）, 2005, ｐｐ．５２９-５３６ * |
| JPN6013027375; Ｍａｊｊｉ Ａ Ｂ ｅｔ ａｌ: 'Ｉｎｈｉｂｉｔｉｏｎ ｏｆ ｃｈｏｒｉｏｃａｐｉｌｌａｒｉｓ ｒｅｇｅｎｅｒａｔｉｏｎ ｗｉｔｈ ｇｅｎｉｓｔｅｉｎ' Ｉｎｖｅｓｔｉｇａｔｉｖｅ ｏｐｈｔｈａｌｍｏｌｏｇｙ ＆ ｖｉｓｕａｌ ｓｃｉｅｎｃｅ Ｖｏｌ．４０，Ｎｏ．７, 1999, ｐｐ．１４７７-１４８６ * |
| JPN6013047931; 天野正文 他: '黒大豆種皮エキスの機能性について（視機能改善効果）' Ｆｏｏｄ ｓｔｙｌｅ ２１ Ｖｏｌ．１０，Ｎｏ．１０, 2006, ｐｐ．７２-７５ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9096795B2 (en) | 2009-05-22 | 2015-08-04 | Merck Patent Gmbh | Liquid crystal display |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102036675A (zh) | 2011-04-27 |
| US20090214681A1 (en) | 2009-08-27 |
| EP2262515A2 (en) | 2010-12-22 |
| WO2009108577A2 (en) | 2009-09-03 |
| AU2009219468A1 (en) | 2009-09-03 |
| US8883230B2 (en) | 2014-11-11 |
| WO2009108577A3 (en) | 2009-11-19 |
| AU2009219468A8 (en) | 2010-11-04 |
| CA2729129A1 (en) | 2009-09-03 |
| TW200938216A (en) | 2009-09-16 |
| KR20110004370A (ko) | 2011-01-13 |
| EP2262515B1 (en) | 2014-07-23 |
| AU2009219468B2 (en) | 2014-08-07 |
| TWI488633B (zh) | 2015-06-21 |
| CN102036675B (zh) | 2012-05-30 |
| EP2262515A4 (en) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3634456B1 (en) | Composition for use in treating retinal diseases | |
| TW201309208A (zh) | 用於營養保養修養多種幹細胞之食品配方及其製造方法 | |
| KR20140037006A (ko) | 매스틱 검의 산성 추출물을 포함하는 조성물 | |
| WO2023024332A1 (zh) | 一种组合物在制备预防和治疗脑卒中药物中的应用 | |
| JP6474114B2 (ja) | 睡眠障害の治療用のカノコソウ根抽出物とラベンダーオイルの組合わせ | |
| JP2021505650A (ja) | 眼用薬物製剤及びその使用 | |
| JP2025026996A (ja) | Ｈｉｆ抑制用組成物 | |
| AU2009219468B2 (en) | Use of black soybean for treating ophthalmic diseases | |
| US20180235904A1 (en) | Cannabidiol compositions including mixtures and uses thereof | |
| CN103596581A (zh) | 脂联素产生促进剂、以及含脂联素产生促进剂的药物组合物、食品与饮料、及饲料 | |
| US20200306252A1 (en) | Composition for preventing and/or treating dementia | |
| JP7304585B2 (ja) | 後眼部異常の予防及び／又はリスク軽減用食品組成物 | |
| CN112370496A (zh) | 枸杞叶有效成分在制备预防或治疗肝纤维化药物中的应用 | |
| KR101636345B1 (ko) | 노회 추출물 또는 이의 분획물을 함유하는 갑상선 질환의 예방 또는 치료용 조성물 | |
| CN107854609A (zh) | 红参、麦冬、五味子组合物用于制备治疗抑郁症的药物的用途 | |
| CN112043789A (zh) | 用于预防或治疗尼古丁成瘾的含有阔叶山麦冬提取物作为活性成分的组合物 | |
| WO2016131320A1 (zh) | Nadph在制备治疗心脏疾病药物中的应用 | |
| KR102950218B1 (ko) | 잎들깨 추출물을 유효성분으로 포함하는 눈 건강 개선용 조성물 | |
| TW201500049A (zh) | 具有護眼功能之中藥材組成物及其製造方法 | |
| CN114984196B (zh) | 用于防治动脉硬化的天然植物组合物、制备方法及应用 | |
| KR102210855B1 (ko) | 장 누수 증후군 예방 또는 치료용 약학적 조성물 | |
| KR102067707B1 (ko) | 마클루라 푸베센스 추출물 또는 분획물을 유효성분으로 함유하는, 뇌신경 보호용 조성물 | |
| KR20240154479A (ko) | 안질환 예방, 개선 또는 치료용 조성물 | |
| HK40121618A (zh) | 一种中药组合物在制备用於抑郁症药物中的应用 | |
| CN119970962A (zh) | 一种中药组合物在制备用于抑郁症药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120123 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120123 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130611 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130904 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140106 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140311 |